International Association For The Study Of Lung Cancer
International Association For The Study Of Lung Cancer shows strong revenue growth and zero reported officer compensation.
EIN: 200499338 · Denver, CO · NTEE: S41 · Updated: 2026-03-28
Is International Association For The Study Of Lung Cancer Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
International Association For The Study Of Lung Cancer directs 80% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About International Association For The Study Of Lung Cancer
International Association For The Study Of Lung Cancer (EIN: 200499338) is a nonprofit organization based in Denver, CO, classified under NTEE code S41. The organization reported total revenue of $29.2M and total assets of $35.6M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of International Association For The Study Of Lung Cancer's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
International Association For The Study Of Lung Cancer is a large nonprofit that has been operating for 19 years, with 14 years of IRS 990 filings on record (2010–2023). Revenue has grown at a compound annual rate of 15.5%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $24.6M |
| Total Expenses | $20.1M |
| Surplus / Deficit | +$4.5M |
| Total Assets | $31.0M |
| Total Liabilities | $10.2M |
| Net Assets | $20.9M |
| Operating Margin | 18.2% |
| Debt-to-Asset Ratio | 32.8% |
| Months of Reserves | 18.5 months |
Financial Health Grade: A
In 2023, International Association For The Study Of Lung Cancer reported a surplus of $4.5M with revenue exceeding expenses, holds 18.5 months of operating reserves (strong position), has a debt-to-asset ratio of 32.8% (moderate leverage).
Financial Trends
Over 14 years of filings (2010–2023), International Association For The Study Of Lung Cancer's revenue has grown at a compound annual growth rate (CAGR) of 15.5%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +113.1% | +37.7% | +22.2% |
| 2022 | -15.6% | +24.4% | +8.9% |
| 2021 | +98.8% | +16.5% | +6.4% |
| 2020 | -63.4% | -43.4% | +2.2% |
| 2019 | +34.1% | +23.0% | +15.2% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 2000 |
| IRS Ruling Date | 2007 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates International Association For The Study Of Lung Cancer with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 15%
- programs: 80%
- fundraising: 5%
According to IRS 990 filings, International Association For The Study Of Lung Cancer allocates its expenses as follows: admin: 15%, programs: 80%, fundraising: 5%. With 80% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $4.5M, with revenue exceeding expenses.
- Debt-to-asset ratio: 32.8%.
Executive Compensation Analysis
The International Association For The Study Of Lung Cancer consistently reports 0% officer compensation across all available filings, which is exceptional for an organization of its size with latest revenue of $29,166,899 and assets of $35,555,926. This suggests either a volunteer-led executive team or that compensation is categorized differently, but as reported, it indicates a strong commitment to directing funds to its mission.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of International Association For The Study Of Lung Cancer's IRS 990 filings:
- Lack of detailed expense breakdown (program, admin, fundraising) in provided data makes full efficiency assessment difficult.
Strengths
The following positive indicators were identified for International Association For The Study Of Lung Cancer:
- Consistent reporting of 0% officer compensation, indicating high transparency and mission focus.
- Significant revenue growth from $11,551,380 in 2022 to $24,616,047 in 2023, demonstrating strong financial momentum.
- Healthy asset-to-liability ratio, with $31,025,690 in assets against $10,161,297 in liabilities in 2023, indicating strong solvency.
- Substantial and growing asset base, reaching $35,555,926, providing a solid foundation for future operations.
Frequently Asked Questions about International Association For The Study Of Lung Cancer
Is International Association For The Study Of Lung Cancer a legitimate charity?
Based on AI analysis of IRS 990 filings, International Association For The Study Of Lung Cancer (EIN: 200499338) some concerns. Mission Score: 85/100. 1 red flag identified, 4 strengths noted.
How does International Association For The Study Of Lung Cancer spend its money?
International Association For The Study Of Lung Cancer directs 80% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to International Association For The Study Of Lung Cancer tax-deductible?
International Association For The Study Of Lung Cancer is registered as a tax-exempt nonprofit (EIN: 200499338). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Is the International Association For The Study Of Lung Cancer financially stable?
Yes, the organization appears financially stable. Its assets of $35,555,926 significantly outweigh its liabilities, and it has shown strong revenue growth, particularly from $11,551,380 in 2022 to $24,616,047 in 2023.
How transparent is the International Association For The Study Of Lung Cancer regarding executive pay?
The organization demonstrates high transparency regarding executive pay by consistently reporting 0% officer compensation across all 14 available IRS 990 filings, indicating that no portion of its expenses is allocated to officer salaries as reported.
Has the organization's revenue been consistent?
No, the organization's revenue has fluctuated significantly, ranging from a low of $5,595,243 in 2014 to a high of $24,616,047 in 2023, with a notable dip in 2020 to $6,883,020.
Filing History
IRS 990 filing history for International Association For The Study Of Lung Cancer showing financial trends over 14 years of public records:
Over 14 years of IRS 990 filings (2010–2023), International Association For The Study Of Lung Cancer's revenue has grown by 550%, moving from $3.8M to $24.6M. Total assets increased by 266% over the same period, from $8.5M to $31.0M. Total functional expenses rose by 459.3%, from $3.6M to $20.1M. In its most recent filing year (2023), International Association For The Study Of Lung Cancer reported a surplus of $4.5M, with revenue exceeding expenses. The organization holds $10.2M in liabilities against $31.0M in assets (debt-to-asset ratio: 32.8%), resulting in net assets of $20.9M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $24.6M | $20.1M | $31.0M | $10.2M | — | — |
| 2022 | $11.6M | $14.6M | $25.4M | $10.2M | — | View 990 |
| 2021 | $13.7M | $11.8M | $23.3M | $6.1M | — | View 990 |
| 2020 | $6.9M | $10.1M | $21.9M | $9.1M | — | View 990 |
| 2019 | $18.8M | $17.8M | $21.4M | $6.4M | — | View 990 |
| 2018 | $14.0M | $14.5M | $18.6M | $4.3M | — | View 990 |
| 2017 | $14.7M | $14.8M | $19.4M | $5.0M | — | View 990 |
| 2016 | $15.2M | $12.8M | $19.7M | $5.6M | — | View 990 |
| 2015 | $15.0M | $11.5M | $16.8M | $5.2M | — | View 990 |
| 2014 | $5.6M | $5.0M | $12.5M | $4.1M | — | View 990 |
| 2013 | $11.2M | $10.7M | $10.7M | $2.8M | — | View 990 |
| 2012 | $3.8M | $4.8M | $9.2M | $2.2M | — | View 990 |
| 2011 | $12.6M | $12.5M | $9.1M | $1.6M | — | View 990 |
| 2010 | $3.8M | $3.6M | $8.5M | $912K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $24.6M, expenses of $20.1M, and assets of $31.0M (revenue +113.1% year-over-year).
- 2022: Revenue of $11.6M, expenses of $14.6M, and assets of $25.4M (revenue -15.6% year-over-year).
- 2021: Revenue of $13.7M, expenses of $11.8M, and assets of $23.3M (revenue +98.8% year-over-year).
- 2020: Revenue of $6.9M, expenses of $10.1M, and assets of $21.9M (revenue -63.4% year-over-year).
- 2019: Revenue of $18.8M, expenses of $17.8M, and assets of $21.4M (revenue +34.1% year-over-year).
- 2018: Revenue of $14.0M, expenses of $14.5M, and assets of $18.6M (revenue -4.5% year-over-year).
- 2017: Revenue of $14.7M, expenses of $14.8M, and assets of $19.4M (revenue -3.2% year-over-year).
- 2016: Revenue of $15.2M, expenses of $12.8M, and assets of $19.7M (revenue +1.0% year-over-year).
- 2015: Revenue of $15.0M, expenses of $11.5M, and assets of $16.8M (revenue +168.3% year-over-year).
- 2014: Revenue of $5.6M, expenses of $5.0M, and assets of $12.5M (revenue -50.1% year-over-year).
- 2013: Revenue of $11.2M, expenses of $10.7M, and assets of $10.7M (revenue +195.3% year-over-year).
- 2012: Revenue of $3.8M, expenses of $4.8M, and assets of $9.2M (revenue -69.9% year-over-year).
- 2011: Revenue of $12.6M, expenses of $12.5M, and assets of $9.1M (revenue +232.8% year-over-year).
- 2010: Revenue of $3.8M, expenses of $3.6M, and assets of $8.5M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for International Association For The Study Of Lung Cancer:
Data Sources and Methodology
This transparency report for International Association For The Study Of Lung Cancer is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.